Publications
Detailed Information
A Hepatitis B Virus-Derived Peptide Can Inhibit Infection of Human Lung Cells with SARS-CoV-2 in a Type-1 Interferon-Dependent Manner
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Yu-Min | - |
dc.contributor.author | Jeong, Hyein | - |
dc.contributor.author | Park, Uni | - |
dc.contributor.author | Cho, Nam-Hyuk | - |
dc.contributor.author | Kim, Bum-Joon | - |
dc.date.accessioned | 2023-04-18T06:22:17Z | - |
dc.date.available | 2023-04-18T06:22:17Z | - |
dc.date.created | 2021-08-09 | - |
dc.date.created | 2021-08-09 | - |
dc.date.created | 2021-08-09 | - |
dc.date.created | 2021-08-09 | - |
dc.date.issued | 2021-07 | - |
dc.identifier.citation | Viruses, Vol.13 No.7, p. 1227 | - |
dc.identifier.issn | 1999-4915 | - |
dc.identifier.uri | https://hdl.handle.net/10371/190049 | - |
dc.description.abstract | The current COVID-19 pandemic has highlighted the urgent need to develop effective therapeutic strategies. We evaluated the in vitro antiviral effect against SARS-CoV-2 of a hepatitis B virus (HBV) hexamer peptide, Poly6, which is capable of eliciting an antiviral effect against human immunodeficiency virus -1 (HIV-1), as a novel HIV-1 integrase inhibitor, and a strong anticancer immune response in an IFN-I-dependent manner, as a novel potential adjuvant in anticancer immunotherapy. Here, we report that Poly6 exerts an anti-SARS-CoV-2 effect, with an estimated 50% inhibitory concentration of 2.617 mu M, in the human bronchial epithelial cell line, Calu-3 but not in Vero-E6 cells, which are deficient in type 1 interferon (IFN-I) signaling. We proved via assays based on mRNA profiles, inhibitors, or blocking antibodies that Poly6 can exert an anti-SARS-CoV-2 effect in an IFN-I-dependent manner. We also found that Poly6 inhibits IL-6 production enhanced by SARS-CoV-2 in infected Calu-3 cells at both the transcription and the translation levels, mediated via IL-10 induction in an IFN-I-dependent manner. These results indicate the feasibility of Poly6 as an IFN-I-inducing COVID-19 drug with potent antiviral and anti-inflammatory activities. | - |
dc.language | 영어 | - |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | - |
dc.title | A Hepatitis B Virus-Derived Peptide Can Inhibit Infection of Human Lung Cells with SARS-CoV-2 in a Type-1 Interferon-Dependent Manner | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/v13071227 | - |
dc.citation.journaltitle | Viruses | - |
dc.identifier.wosid | 000677038600001 | - |
dc.identifier.scopusid | 2-s2.0-85109421027 | - |
dc.citation.number | 7 | - |
dc.citation.startpage | 1227 | - |
dc.citation.volume | 13 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Cho, Nam-Hyuk | - |
dc.contributor.affiliatedAuthor | Kim, Bum-Joon | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | I INTERFERONS | - |
dc.subject.keywordPlus | COVID-19 | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | BETA | - |
dc.subject.keywordAuthor | SARS-CoV-2 | - |
dc.subject.keywordAuthor | type I IFN (IFN-I) | - |
dc.subject.keywordAuthor | a hepatitis B virus (HBV)-derived peptide | - |
dc.subject.keywordAuthor | Poly6 | - |
dc.subject.keywordAuthor | IL-6 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.